Wynik wyszukiwania w bazie Polska Bibliografia Lekarska GBL

Zapytanie: HACZYŃSKI
Liczba odnalezionych rekordów: 1



Przejście do opcji zmiany formatu | Wyświetlenie wyników w wersji do druku
1/1

Tytuł oryginału: Comparative study of cefaclor AF vs cefuroxime axetil in acute exacerbations of chronic bronchitis.
Autorzy: Haczyński Józef, Chyczewska Elżbieta, Grzelewska-Rzymowska Iwona, Małolepszy Józef, Marcinowska-Suchowierska Ewa, Milanowski Janusz, Oklek Kazimierz, Płusa Tadeusz, Słomiński Marek, Szmygin Katarzyna, Rek Mirosław
Źródło: Med. Sci. Monitor 2002: 8 (1) s.PI1-PI7, il., tab., bibliogr. 38 poz.
Sygnatura GBL: 313,278

Hasła klasyfikacyjne GBL:
  • toksykologia
  • pulmonologia

    Typ dokumentu:
  • praca kliniczna
  • tytuł obcojęzyczny

    Wskaźnik treści:
  • ludzie
  • płeć męska
  • płeć żeńska
  • dorośli 45-64 r.ż.
  • dorośli = 65 r.ż.

    Streszczenie angielskie: Background: Acute exacerbations of chronic bronchitis (AECB) are the most common complication of chronic bronchitis. The majority of AECB are caused by infection. The choice of appropriate antibacterial therapy for AECB is becoming more difficult and is usually empirically, Cefaclor and cefruoxime are used for ambulatory treatment of AECB. Material/Methods: This multicenter, randomized, single blind study was undertaken in order to compare efficacy and safety of cefaclor AF (500 mg BID) and cefuroxime axetil (250 mg BID) in 10 days treatment of ambulatory patients with SECB. 170 adults were enrolled into the study. Clinical responses were assessed on 17th - 24th day after randomization. Results: Both antibiotics had high over 97 p.c. effectiveness in the treatment of AECB. There was stastically 1.7 times higher rate of patients with cough release after cefaclor treatment compared to cefuroxime (p 0.03). There was a significantly 2.25 higher rate of patients with AECB symptoms release like: increasing dyspnea, sputum volume and sputum purulence or cough in cefaclor group compard to cefuroxime (p 0.0187). Both treatment resulted in significant improvement of pulmonary peak expiratory flow (PEF). There were no differences between the rates of gastrointestinal and other side effects in both groups. Conclusions: 1. Cefaclor and cefruroxime have similar high efficacy and safety in 10 days treatment of patients with AECB. 2. Cefaclor treatment significantly higher 2.25 times reduces the rate of principle symptoms of AECB compared to cefuroxime. 3. Both antibiotics treatment significantly increase PEF, with higher tendency observed in after cefaclor treatment.

    stosując format: